Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: A structured meta-analysis

European Radiology

Volumn 19, Issue 4, 2009, Pages 951-959

  Vente, M A D ^a   Wondergem, M ^a   van der Tweel, I ^b   van den Bosch, M A A J ^a   Zonnenberg, B A ^a   Lam, M G E H ^a   van het Schip, A D ^a   Nijsen, J F W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Colorectal; HCC; Meta analysis; Radioembolization; Yttrium 90

Indexed keywords

FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GLASS; MICROSPHERE; OXALIPLATIN; RESIN; YTTRIUM 90; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; IRINOTECAN; PLATINUM COMPLEX; YTTRIUM;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER CLASSIFICATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; INOPERABLE CANCER; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CHEMOEMBOLIZATION; COLORECTAL NEOPLASMS; LIVER NEOPLASMS; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; GLASS; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MICROSPHERES; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 62649136459     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-008-1211-7     Document Type: Article

References (67)

1. Salem R, Thurston K (2006) Radioembolization with yttrium-90 microspheres: A state-of-the-art brachytherapy treatment for primary and seCondary liver malignancies: Part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 17:1571-1593
2. Vente M, Hobbelink M, van het Schip A et al (2007) Radionuclide liver cancer therapies: From concept to current clinical status. Anticancer Agents Med Chem 7:441-459
3. Bierman H, Byron R, Kelley K et al (1951) Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. J Natl Cancer Inst 12:107-131
4. Gulec S, Fong Y (2007) Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch Surg 142:675-682
5. Murthy R, Kamat P, Nunez R et al (2008) Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 19:145-151
6. Sato K, Lewandowski R, Mulcahy M et al (2008) Unresectable chemorefractory liver metastases: Radioembolization with 90 Y microspheres-safety, efficacy, and survival. Radiol 247:507-515
7. Jakobs T (2007) mCRC treament outcomes: US and EU data review. Presented at the emerging trends in radioembolisation using microspheres, clinical workshop, Chicago, IL, 4-5 May 2007
8. SIRTeX Medical Ltd (2008) Publications (international). Available via http://www.sirtex.com/content.cfm?sec=usa&MenuID=1120&ID= F4CC0AB7. Accessed 1 May 2008
9. MDS Nordion Inc (2008) Publications. Available via http://www.nordion.com/therasphere/physicians-publications-eu.asp. Accessed 1 May 2008
10. Carr B (2004) Hepatocellular carcinoma: Current management and future trends. Gastroenterology 127:S218-S224
11. Andrews J, Walker S, Ackermann R et al (1994) Hepatic radioembolization with yttrium-90 containing glass microspheres: Preliminary results and clinical follow-up. J Nucl Med 35:1637-1644
12. Hamza T, Van Houwelingen H, Stijnen T (2008) The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 61:41-51
13. Gray B, Anderson J, Burton M et al (1992) Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg 62:105-110
14. Gray B, Van Hazel G, Hope M et al (2001) Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy. Ann Oncol 12:1711-1720
15. Van Hazel G, Blackwell A, Anderson J et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78-85
16. Stubbs R, Cannan R, Mitchell A (2001) Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 5:294-302
17. Murthy R, Xiong H, Nunez R et al (2005) Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: Preliminary results. J Vasc Interv Radiol 16:937-945
18. Lim L, Gibbs P, Yip D et al (2005) Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 35:222-227
19. Lim L, Gibbs P, Yip D et al (2005) A prospective evaluation of treatment with selective internal radiation therapy (SIR-Spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 5:132-137
20. Mancini R, Carpanese L, Sciuto R et al (2006) A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-Spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: Preliminary results on toxicity and response rates. In Vivo 20:711-714
21. Kennedy A, Coldwell D, Nutting C et al (2006) Resin (90)Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys 65:412-425
22. Stubbs R, O'Brien I, Correia M (2006) Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 76:696-703
23. Sharma R, Van Hazel G, Morgan B et al (2007) Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25:1099-1106
24. Jakobs T, Hoffmann R, Poepperl G et al (2007) Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol 17:1320-1330
25. Anderson J, Goldberg J, Bessent R et al (1992) Glass yttrium-90 microspheres for patients with colorectal liver metastases. Radiother Oncol 25:137-139
26. Wong C, Salem R, Raman S et al (2002) Evaluating 90 Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18 F]FDG PET: A comparison with CT or MRI. Eur J Nucl Med Mol Imaging 29:815-820
27. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: Response to treatment at targeted doses of 135-150 Gy as measured by [18 F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 16:1641-1651
28. Gray B, Van Hazel M, Buck M et al (2000) Treatment of colorectal liver metastases with SIR-Spheres plus chemotherapy. GI Cancer 3:249-257
29. Stubbs R, Cannan R, Mitchell A et al (1999) An initial experience with selective internal radiation therapy (SIRT) for non-resectable colorectal liver metastases. GI Cancer 3:135-143
30. Geschwind J, Salem R, Carr B et al (2004) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127:S194-S205
31. Lau W, Leung W, Ho S et al (1994) Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: A phase I and II study. Br J Cancer 70:994-999
32. Lau W, Ho S, Leung T et al (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40:583-592
33. Sangro B, Bilbao J, Boan J et al (2006) Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66:792-800
34. Houle S, Yip T, Sheperd F et al (1989) Hepatocellular carcinoma: Pilot trial of treatment with Y-90 microspheres. Radiology 172:857-860
35. Dancey J, Shepherd F, Paul K et al (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41:1673-1681
36. Carr B (2004) Hepatic arterial 90yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: Interim safety and survival data on 65 patients. Liver Transpl 10(Suppl 2):S107-S110
37. Liu M, Uaje M, Al Ghazi M et al (2004) Use of yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am Surg 70:947-953
38. Salem R, Lewandowski R, Atassi B et al (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627-1639
39. Sato K, Lewandowski R, Bui J et al (2006) Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere®): Assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 29:522-529
40. Kulik L, Atassi B, Van Holsbeeck L et al (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94:572-586
41. Therasse P, Arbuck S, Eisenhauer E et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
42. Murthy R, Nunez R, Szklaruk J et al (2005) Yttrium-90 microsphere therapy for hepatic malignancy: Devices, indications, technical considerations, and potential complications. Radiographics 25(Suppl 1):S41-S55
43. Pöpperl G, Helmberger T, Münzing W et al (2005) Selective internal radiation therapy with SIR-Spheres® in patients with nonresectable liver tumors. Cancer Biother Radiopharm 20:200-208
44. Saar B, Kellner-Weldon F (2008) Radiological diagnosis of hepatocellular carcinoma. Liver Int 28:189-199
45. Salem R, Thurston K (2006) Radioembolization with 90 yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies part 2: Special topics. J Vasc Interv Radiol 17:1425-1439
46. Coldwell D, Kennedy A (2005) Treatment of hepatic metastases from breast cancer with yttrium-90 SIR-Spheres radioembolization. Society of Interventional Radiology 2005 annual meeting, New Orleans, LA.
47. Goin J, Dancey J, Roberts C et al (2004) Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: Trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med 3:49-56
48. Murthy R, Brown D, Salem R et al (2007) Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 18:553-562
49. Carretero C, Munoz-Navas M, Betes M et al (2007) Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol 102:1216-1220
50. Salem R, Thurston KG (2006) Radioembolization with 90 yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies part 1: Technical and methodologic considerations. J Vasc Interv Radiol 17:1251-1278
51. Lewandowski R, Salem R (2004) Incidence of radiation cholecystitis in patients receiving Y-90 treatment for unresectable liver malignancies [Abstract]. J Vasc Interv Radiol 15:S162
52. Leung T, Lau W, Ho S et al (1995) Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33:919-924
53. Salem R, Lewandowski R, Sato K et al (2007) Technical aspects of radioembolization with 90 Y microspheres. Tech Vasc Interv Radiol 1:12-29
54. Neff R, Abdel-Misih R, Khatri J et al (2008) The toxicity of liver directed yttrium-90 micrcospheres in primary and metastatic liver tumors. Cancer Invest 26:173-177
55. Wollner I, Knutsen C, Ullrich K et al (1987) Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs. Cancer Res 47:3285-3290
56. Atassi B, Bangash A, Bahrani A et al (2008) Multimodality imaging following 90Y radioembolization: A comprehensive review and pictorial essay. Radiographics 28:81-99
57. Bienert M, McCook B, Carr B et al (2005) (90)Y microsphere treatment of unresectable liver metastases: Changes in (18)F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 32:778-787
58. Wong C, Qing F, Savin M et al (2005) Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18 F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 16:1101-1106
59. Kwee TC, Takahara T, Ochiai R, Nievelstein RAJ, Luijten PR et al (2008) Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): Features and potential applications in oncology. Eur Radiol 18:1937-1952. doi: 10.1007/s00330-008-0968-z
60. US National Institutes of Health (NIH) Medical Research Center. http://clinicalresearch.nih.gov/. Accessed 1 May 2008
61. Bangash A, Atassi B, Kaklamani V et al (2007) 90Y radioembolization of metastatic breast cancer to the liver: Toxicity, imaging response, survival. J Vasc Interv Radiol 18:621-628
62. Coldwell D, Kennedy A, Nutting C (2007) Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 69:800-804
63. Gulec S, Mesoloras G, Dezarn W et al (2007) Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med 5:15-23
64. Llovet S, Ricci V, Mazzaferro P et al (2007) Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a phase III randomized placebo-controlled trial (SHARP trial) [Abstract]. J Clin Oncol 25:18S
65. Hochster H, Hart R, Hainsworth J et al (2006) Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-study [Abstract]. J Clin Oncol 24:148s
66. Hochster H, Welles L, Hart R et al (2005) Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies [Abstract]. J Clin Oncol 23:249s
67. 90Y microspheres + ChemoTx first line patients with mCRC. Presented at the emerging trends in radioembolisation using microspheres, clinical workshop, Chicago, IL, 4-5 May 2007